Published on January 10, 2014 at 3:13 AM
Adult ADHD affects as many as 10 million people in the US alone. In adults it can be a serious condition and can severely impair executive function, the ability to organize and plan effectively, hold a job, maintain a long-term relationship or even to safely drive a car. In adults, 75% of ADHD patients have at least one other psychiatric disorder alongside their ADHD. Neurovance is exploring EB-1020 SR's effects on several comorbidities including executive function, mood and emotional dysregulation as secondary endpoints in this study. Complete results from the trial are expected by the end of the first quarter 2014.
"Given the pernicious effects of untreated ADHD, novel treatment options are sorely needed for adults with the disorder," said Timothy E. Wilens, MD, of Massachusetts General Hospital and a leading ADHD expert. Dr. Wilens added, "These preliminary results of EB-1020 SR on ADHD symptoms and overall outcome are very encouraging and certainly warrant further exploration."
EB-1020 SR has shown a low risk of abuse potential in preclinical studies. Other triple reuptake inhibitors in development have been evaluated and have consistently demonstrated a low risk of abuse potential. Although a definitive abuse liability study has not yet been initiated with EB-1020 SR, a less restrictive level of scheduling, compared to stimulants, is anticipated.
According to IMS Health, the US ADHD market was valued at $10.4 billion in 2012, and is one of the fastest growing US pharmaceutical markets. The US prescription market is roughly equal in size between adults and children; however, prescriptions are growing at a rate nearly three times faster in adults. Although ADHD markets outside of the US are less well developed, they are growing rapidly. In 2012 IMS reported ADHD sales growing from $569 million in 2007 to just over $1 billion in 2011, a 16% compound annual growth rate.
Source: Neurovance Inc.